In the study by Villalva, KRAS mutational status did not facilitate the metastasis of NSCLC.60 This finding is consistent with several studies that showed that KRAS mutations were related to the suppression of progression.90, 91 The overall mutation rate of KRAS in primary tumors was not significantly different from that of matched metastases in a meta‐analysis by Wang; the odds ratio was 1.224 (95% CI: 0.808‐1.856, P = 0.340).92 That study did not find significant differences in overall KRAS mutation rates between primary and metastatic NSCLC either. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.